NVS - Genomic Medicine: Fall 2019 Tracking Update
Pixabay
Data is the foundation of investing. Most investment focuses on data in the form of earnings per share, PE multiple, revenue growth, PEG ratio, etc. Biotech clinical results are based upon data. This article is a vehicle to present alternative data used to help understand clinical genomic medicine companies while we wait for them to mature and provide data relevant to a commercial-stage company.
Cell and gene therapy companies continue to show clinical progress but have yet to reach the point where approved or commercially launched products provide any valuation support. The autologous cell